China Health Group Inc. (the “Company”), listed under stock code 08225, announced updated progress regarding the recovery of trade receivables originally amounting to RMB128 million, as disclosed in the 2024 Annual Report. According to the Company, RMB11,086,946 has been retrieved from related-party debtors as of November 30, 2025, through a combination of formal communication efforts and initiated arbitration proceedings.

The Company further disclosed that RMB4,451,430 has been successfully collected from non-related parties who maintain sound repayment willingness. Measures are also in place for customers with long-overdue balances or operational difficulties, including the engagement of professional institutions for assessment and legal proceedings. In instances of high collection difficulty, additional legal actions such as inclusion in the list of enforcement targets and close monitoring of asset status have been implemented.

Internally, the Company established a dedicated Trade Receivable Management Committee to streamline controls from customer credit evaluation to payment period oversight, aiming to prevent new risks. Plans moving forward include ongoing negotiations, execution of arbitration awards, and potential civil lawsuits to maximize recoveries. The Company cautions that multiple factors could affect the ultimate repayment outcome and will disclose further developments in accordance with relevant regulations.